相关实验视频

Updated: Jan 7, 2026

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

作为动脉样硬化进展和治疗反应的生物标志物的TLR2,CCR1,IRF8和CCL4:一项多omics研究

Wangwei Zhou¹, Min Huang¹, Han Li¹

¹Cardiology Department, Liuzhou People's Hospital, Liuzhou, Guangxi, China.

|December 30, 2025

概括

这项研究确定了四种新的生物标志物 (收费像受体2,CCR1,干扰素调节因子8,CCL4) 用于动脉样硬化 (AS) 诊断和风险预测. 辛巴斯塔丁显示出作为针对这种血管疾病的向治疗的潜力.

科学领域:

心血管研究研究心血管研究
生物信息学是一种生物信息学.
免疫学免疫学免疫学

背景情况:

动脉样硬化 (AS) 的诊断和治疗受到当前方法的限制.
早期检测和了解斑块生物学对于有效管理至关重要.
现有的治疗方法往往控制症状,而不是解决潜在原因.

研究的目的:

使用生物信息学识别动脉样硬化新型诊断生物标志物.
探索动脉样硬化的潜在向治疗方法.
改善AS的早期检测和个性化治疗策略.

主要方法:

对基因表达 (GSE28829) 和单细胞RNA-seq (GSE159677) 数据的分析.
权重基因共同表达网络分析 (WGCNA) 和差异基因表达分析 (Limma).
机器学习模型,蛋白质-蛋白质相互作用网络,免疫透分析 (CIBERSORT) 和分子对接.

主要成果:

确定了关键基因模块和238个与AS免疫过程相关的差异表达基因.
发现了四种具有高诊断准确度 (AUC>0.8) 的新生物标志物 (通类受体2,CCR1,干扰素调节因子8,CCL4).
开发了用于AS风险预测的强大的名谱,并发现simvastatin显示出针对性治疗的强大潜力.

结论:

收费像受体2,CCR1,干扰素调节因子8和CCL4是AS的有希望的新生物标志物,与免疫通路有关.
开发的诺莫格拉姆模型可以帮助预测AS风险.
西姆瓦斯塔丁显示出作为动脉样硬化向治疗剂的潜力,推进个性化治疗选择.

关键词:

动脉样硬化动脉样硬化诊断生物标志物生物标志物诊断模型诊断模型诊断模型免疫透免疫透是什么?分子对接的分子对接.

更多相关视频

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

In vivo Near Infrared Fluorescence NIRF Intravascular Molecular Imaging of Inflammatory Plaque, a Multimodal Approach to Imaging of Atherosclerosis

In vivo Near Infrared Fluorescence NIRF Intravascular Molecular Imaging of Inflammatory Plaque, a Multimodal Approach to Imaging of Atherosclerosis

Published on: August 4, 2011

相关概念视频

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...